Taysha Gene Therapies executive sold 200,000 shares under a prearranged plan as the stock hit a one-year high.
Taysha Gene Therapies Inc. (NASDAQ:TSHA) president of R&D Nagendran Sukumar sold 200,000 shares for $1.2 million on July 10, 2026, according to an SEC filing. The sale occurred under a Rule 10b5-1 trading plan adopted in June 2025, designed to prevent insider trading concerns.
The stock closed at $6.57 on July 9, 2026, reflecting a 149% one-year return. Sukumar retains 936,410 shares, valued at $5.94 million based on the $6.34 closing price on the sale date. Taysha reported a $129.9 million net loss on $7.5 million revenue for the trailing twelve months.
The company focuses on gene therapies for central nervous system diseases using adeno-associated virus vectors.